Siegel RL, Miller KD, Wagle NS and Jemal A: Cancer statistics, 2023. CA Cancer J Clin. 73:17–48. 2023. View Article : Google Scholar : PubMed/NCBI

Enneli D and Baglan T: The many faces of urothelial carcinomas: An update from pathology to clinical approach and challenges in practice. Urol Res Pract. 49:147–161. 2023. View Article : Google Scholar

Clark PE, Agarwal N, Biagioli MC, Eisenberger MA, Greenberg RE, Herr HW, Inman BA, Kuban DA, Kuzel TM, Lele SM, et al: Bladder Cancer. J Natl Compr Canc Netw. 11:446–475. 2013. View Article : Google Scholar : PubMed/NCBI

Hemminki K: Reactions of ethyleneimine with guanosine and deoxyguanosine. Chem Biol Interact. 48:249–260. 1984. View Article : Google Scholar

Hemminki K and Ludlum DB: Covalent modification of DNA by antineoplastic agents. J Natl Cancer Inst. 73:1021–1028. 1984.

Maanen MJ, Smeets CJ and Beijnen JH: Chemistry, pharmacology and pharmacokinetics of N,N',N' -triethylenethiophosphoramide (ThioTEPA). Cancer Treat Rev. 26:257–268. 2000. View Article : Google Scholar : PubMed/NCBI

Soloway MS and Ford KS: Thiotepa-induced myelosuppression: Review of 670 bladder instillations. J Urol. 130:889–891. 1983. View Article : Google Scholar

Faraj K, Chang YH, Rose KM, Habermann EB, Etzioni DA, Blodgett G, Castle EP, Humphreys MR and Tyson Ii MD: Single-dose perioperative mitomycin-C versus thiotepa for low-grade noninvasive bladder cancer. Can J Urol. 26:9922–9930. 2019.

Chou R, Selph S, Buckley DI, Fu R, Griffin JC, Grusing S and Gore JL: Intravesical therapy for the treatment of nonmuscle invasive bladder cancer: A systematic review and meta-analysis. J Urol. 197:1189–1199. 2017. View Article : Google Scholar

Koch GE, Smelser WW and Chang SS: Side effects of intravesical BCG and chemotherapy for bladder cancer: What they are and how to manage them. Urology. 149:11–20. 2021. View Article : Google Scholar : PubMed/NCBI

Zhang J, Li M, Chen Z, OuYang J and Ling Z: Efficacy of bladder intravesical chemotherapy with three drugs for preventing non-muscle-invasive bladder cancer recurrence. J Healthc Eng. 2021:23607172021.PubMed/NCBI

Li R, Li Y, Song J, Gao K, Chen K, Yang X, Ding Y, Ma X, Wang Y, Li W, et al: Intravesical gemcitabine versus mitomycin for non-muscle invasive bladder cancer: A systematic review and meta-analysis of randomized controlled trial. BMC Urol. 20:972020. View Article : Google Scholar

Wang L, Huang S, Zhang P and Li H, Li Z, Xue L, Wang Z, Chen Q, Fu D, Luo Q and Li H: The application of gemcitabine and pirarubicin in patients with non-muscle invasive bladder cancer. J Cancer Res Clin Oncol. 149:8945–8949. 2023. View Article : Google Scholar

Kim HS and Seo HK: Immune checkpoint inhibitors for urothelial carcinoma. Investig Clin Urol. 59:285–296. 2018. View Article : Google Scholar

Dasari S and Tchounwou PB: Cisplatin in cancer therapy: Molecular mechanisms of action. Eur J Pharmacol. 740:364–378. 2014. View Article : Google Scholar

Du Z, Yin H, Zhao S, Ma Y, Sun Z, Dong B, Zhu M, Zhu C, Peng J and Yang T: Case report: Gemcitabine intravesical hyperthermic infusion combined with tislelizumab in muscle invasive bladder urothelium carcinoma. Front Oncol. 12:10626552022. View Article : Google Scholar

Liu K, Zhu J, Song YX, Wang X, Zhou KC, Lu Y and Liu XQ: Thermal intravesical chemotherapy reduce recurrence rate for non-muscle invasive bladder cancer patients: A meta-analysis. Front Oncol. 10:292020. View Article : Google Scholar

Ruan Q, Ding D, Wang B, He C, Ren X, Feng Z, Pang Z, Wang J, Zhang X, Tang H, et al: A multi-institutional retrospective study of hyperthermic plus intravesical chemotherapy versus intravesical chemotherapy treatment alone in intermediate and high risk nonmuscle-invasive bladder cancer. Cancer Biol Med. 18:308–317. 2021. View Article : Google Scholar : PubMed/NCBI

van der Heijden AG, Verhaegh G, Jansen CF, Schalken JA and Witjes JA: Effect of hyperthermia on the cytotoxicity of 4 chemotherapeutic agents currently used for the treatment of transitional cell carcinoma of the bladder: An in vitro study. J Urol. 173:1375–1380. 2005. View Article : Google Scholar

Han MA, Maisch P, Jung JH, Hwang JE, Narayan V, Cleves A, Hwang EC and Dahm P: Intravesical gemcitabine for non-muscle invasive bladder cancer. Cochrane Database Syst Rev. 6:CD0092942021.PubMed/NCBI

Kuperus JM, Busman RD, Kuipers SK, Broekhuizen HT, Noyes SL, Brede CM, Tobert CM and Lane BR: Comparison of side effects and tolerability between intravesical bacillus calmette-guerin, reduced-dose BCG and gemcitabine for non-muscle invasive bladder cancer. Urology. 156:191–198. 2021. View Article : Google Scholar : PubMed/NCBI

Shelley MD, Jones G, Cleves A, Wilt TJ, Mason MD and Kynaston HG: Intravesical gemcitabine therapy for non-muscle invasive bladder cancer (NMIBC): A systematic review. BJU Int. 109:496–505. 2012. View Article : Google Scholar

Massadeh S, Almohammed I, Barhoush E, Omer M, Aldhawi N, Almalik A and Alaamery M: Development of epirubicin-loaded biocompatible polymer PLA-PEG-PLA Nanoparticles: Synthesis, characterization, stability, and in vitro anticancerous assessment. Polymers (Basel). 13:12122021. View Article : Google Scholar : PubMed/NCBI

Cersosimo RJ and Hong WK: Epirubicin: A review of the pharmacology, clinical activity, and adverse effects of an adriamycin analogue. J Clin Oncol. 4:425–439. 1986. View Article : Google Scholar

Mantso T, Goussetis G, Franco R, Botaitis S, Pappa A and Panayiotidis M: Effects of hyperthermia as a mitigation strategy in DNA damage-based cancer therapies. Semin Cancer Biol. 37–38. 96–105. 2016.

Brummelhuis ISG, Wimper Y, Witjes-van Os HGJM, Arends TJH, van der Heijden AG and Witjes JA: Long-Term experience with radiofrequency-induced hyperthermia combined with intravesical chemotherapy for non-muscle invasive bladder cancer. Cancers (Basel). 13:3772021. View Article : Google Scholar : PubMed/NCBI

Owusu RA, Abern MR and Inman BA: Hyperthermia as adjunct to intravesical chemotherapy for bladder cancer. Biomed Res Int. 2013:2623132013. View Article : Google Scholar

Wu CC, Hsu YT and Chang CL: Hyperthermic intraperitoneal chemotherapy enhances antitumor effects on ovarian cancer through immune-mediated cancer stem cell targeting. Int J Hyperthermia. 38:1013–1022. 2021. View Article : Google Scholar

Qiao X, van der Zanden SY, Wander DPA, Borràs DM, Song JY, Li X, van Duikeren S, van Gils N, Rutten A, van Herwaarden T, et al: Uncoupling DNA damage from chromatin damage to detoxify doxorubicin. Proc Natl Acad Sci USA. 117:15182–15192. 2020. View Article : Google Scholar : PubMed/NCBI

Schooneveldt G, Bakker A, Balidemaj E, Chopra R, Crezee J, Geijsen ED, Hartmann J, Hulshof MC, Kok HP, Paulides MM, et al: Thermal dosimetry for bladder hyperthermia treatment. An overview. Int J Hyperthermia. 32:417–433. 2016. View Article : Google Scholar

Van Bree C, Beumer C, Rodermond HM, Haveman J and Bakker PJ: Effectiveness of 2′,2′difluorodeoxycytidine (Gemcitabine) combined with hyperthermia in rat R-1 rhabdomyosarcoma in vitro and in vivo. Int J Hyperthermia. 15:549–556. 1999. View Article : Google Scholar

Takahashi A, Yamamoto Y, Yasunaga M, Koga Y, Kuroda J, Takigahira M, Harada M, Saito H, Hayashi T, Kato Y, et al: NC-6300, an epirubicin-incorporating micelle, extends the antitumor effect and reduces the cardiotoxicity of epirubicin. Cancer Sci. 104:920–925. 2013. View Article : Google Scholar

Kageyama S, Maeda K, Kubota S, Yoshida T, Osafune T, Arai Y, Soga H, Nishikawa Z, Sakano Y, Takimoto K, et al: Single short retention instillation of pirarubicin prevents intravesical recurrence of low-risk non muscle invasive bladder cancer. In Vivo. 35:1141–1145. 2021. View Article : Google Scholar : PubMed/NCBI

Zheng SE, Xiong S, Lin F, Qiao GL, Feng T, Shen Z, Min DL, Zhang CL and Yao Y: Pirarubicin inhibits multidrug-resistant osteosarcoma cell proliferation through induction of G2/M phase cell cycle arrest. Acta Pharmacol Sin. 33:832–838. 2012. View Article : Google Scholar : PubMed/NCBI

Okamura K, Ono Y, Kinukawa T, Matsuura O, Yamada S, Ando T, Fukatsu T, Ohno Y and Ohshima S; Nagoya University Urological Oncology Group, : Randomized study of single early instillation of (2′R)-4′-O-tetrahydropyranyl-doxorubicin for a single superficial bladder carcinoma. Cancer. 94:2363–2368. 2002. View Article : Google Scholar : PubMed/NCBI

Sasaki N, Ikenaka Y, Aoshima K, Aoyagi T, Kudo N, Nakamura K and Takiguchi M: Safety Assessment of Ultrasound-Assisted Intravesical Chemotherapy in Normal Dogs: A Pilot Study. Front Pharmacol. 13:8377542022. View Article : Google Scholar

Zhou J, Li L, Li X, Yu Q, Cui S, Shu K, Liu J, Liu J, Ding D and Du T: Efficacy analysis of a novel thermochemotherapy scheme with pirarubicin for intermediate- and high-risk nonmuscle-invasive bladder cancer: A single-institution nonrandomized concurrent controlled trial. Int J Hyperthermia. 36:868–875. 2019. View Article : Google Scholar

Favoulet P, Benoit L, Osmak L, Polycarpe E, Esquis P, Duvillard C, Guiu B, Rat P, Favre JP and Chauffert B: Prevention of peritoneal carcinomatosis from colon cancer cell seeding using a pirarubicin solution in rats and nude mice. World J Surg. 28:451–456. 2004. View Article : Google Scholar : PubMed/NCBI

Oei AL, Vriend LE, Crezee J, Franken NA and Krawczyk PM: Effects of hyperthermia on DNA repair pathways: One treatment to inhibit them all. Radiat Oncol. 10:1652015. View Article : Google Scholar

Lammers RJ, Witjes JA, Inman BA, Leibovitch I, Laufer M, Nativ O and Colombo R: The role of a combined regimen with intravesical chemotherapy and hyperthermia in the management of non-muscle-invasive bladder cancer: A systematic review. Eur Urol. 60:81–93. 2011. View Article : Google Scholar

Melgarejo Segura MT, Morales Martínez A, Yáñez Castillo Y, Arrabal Polo MÁ, Gómez Lechuga P, Pareja Vílchez M and Arrabal Martín M: Conductive hyperthermic chemotherapy versus electromotive drug administration of mitomycin C as intravesical adjuvant treatment of patients with intermediate or high-risk non-muscle invasive bladder cancer. Urol Oncol. 41:109.e1–109.e8. 2023. View Article : Google Scholar

Guerrero-Ramos F, González-Padilla DA, González-Díaz A, de la Rosa-Kehrmann F, Rodríguez-Antolín A, Inman BA and Villacampa-Aubá F: Recirculating hyperthermic intravesical chemotherapy with mitomycin C (HIVEC) versus BCG in high-risk non-muscle-invasive bladder cancer: Results of the HIVEC-HR randomized clinical trial. World J Urol. 40:999–1004. 2022. View Article : Google Scholar

Conroy S, Pang K, Jubber I, Hussain SA, Rosario DJ, Cumberbatch MG, Catto JWF and Noon AP: Hyperthermic intravesical chemotherapy with mitomycin-C for the treatment of high-risk non-muscle-invasive bladder cancer patients. BJUI Compass. 4:314–321. 2022. View Article : Google Scholar : PubMed/NCBI

Plata A, Guerrero-Ramos F, Garcia C, González-Díaz A, Gonzalez-Valcárcel I, de la Morena JM, Díaz-Goizueta FJ, Del Álamo JF, Gonzalo V, Montero J, et al: Long-Term experience with hyperthermic chemotherapy (HIVEC) Using Mitomycin-C in Patients with non-muscle invasive bladder cancer in Spain. J Clin Med. 10:51052021. View Article : Google Scholar : PubMed/NCBI

Morales A, Eidinger D and Bruce AW: Intracavitary bacillus calmette-guerin in the treatment of superficial bladder tumors. J Urol. 116:180–182. 1976. View Article : Google Scholar

Kamat AM, Flaig TW, Grossman HB, Konety B, Lamm D, O'Donnell MA, Uchio E, Efstathiou JA and Taylor JA III: Consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer. Nat Rev Urol. 12:225–235. 2015. View Article : Google Scholar

Jiang S and Redelman-Sidi G: BCG in bladder cancer immunotherapy. Cancers (Basel). 14:30732022. View Article : Google Scholar : PubMed/NCBI

Kamat AM, Briggman J, Urbauer DL, Svatek R, Nogueras González GM, Anderson R, Grossman HB, Prat F and Dinney CP: Cytokine panel for response to intravesical therapy (CyPRIT): Nomogram of changes in urinary cytokine levels predicts patient response to bacillus calmette-guérin. Eur Urol. 69:197–200. 2016. View Article : Google Scholar

Han J, Gu X, Li Y and Wu Q: Mechanisms of BCG in the treatment of bladder cancer-current understanding and the prospect. Biomed Pharmacother. 129:1103932020. View Article : Google Scholar : PubMed/NCBI

Lamm DL: Bacillus calmette-guerin immunotherapy for bladder cancer. J Urol. 134:40–47. 1985. View Article : Google Scholar

Heckler M, Ali LR, Clancy-Thompson E, Qiang L, Ventre KS, Lenehan P, Roehle K, Luoma A, Boelaars K, Peters V, et al: Inhibition of CDK4/6 Promotes CD8 T-cell memory formation. Cancer Discov. 11:2564–2581. 2021. View Article : Google Scholar : PubMed/NCBI

Chung R, McKiernan J, Arpaia N, Marabelle A and Rouanne M: Neo-Adjuvant immunotherapies: Bladder cancer as a platform for drug development targeting mucosal immunity. Eur J Cancer. 187:58–64. 2023. View Article : Google Scholar : PubMed/NCBI

Leko V, McDuffie LA, Zheng Z, Gartner JJ, Prickett TD, Apolo AB, Agarwal PK, Rosenberg SA and Lu YC: Identification of neoantigen-reactive tumor-infiltrating lymphocytes in primary bladder cancer. J Immunol. 202:3458–3467. 2019. View Article : Google Scholar

Mohamed F, Marchettini P, Stuart OA, Urano M and Sugarbaker PH: Thermal enhancement of new chemotherapeutic agents at moderate hyperthermia. Ann Surg Oncol. 10:463–468. 2003. View Article : Google Scholar

Ji N, Mukherjee N, Shu ZJ, Reyes RM, Meeks JJ, McConkey DJ, Gelfond JA, Curiel TJ and Svatek RS: γδ T cells support antigen-specific αβ T cell-mediated antitumor responses during BCG treatment for bladder cancer. Cancer Immunol Res. 9:1491–1503. 2021. View Article : Google Scholar : PubMed/NCBI

Chen F, Zhang G, Iwamoto Y and See WA: BCG directly induces cell cycle arrest in human transitional carcinoma cell lines as a consequence of integrin cross-linking. BMC Urol. 5:82005. View Article : Google Scholar

Yu DS, Wu CL, Ping SY, Keng C and Shen KH: Bacille Calmette-Guerin can induce cellular apoptosis of urothelial cancer directly through toll-like receptor 7 activation. Kaohsiung J Med Sci. 31:391–397. 2015. View Article : Google Scholar

Sandes E, Lodillinsky C, Cwirenbaum R, Argüelles C, Casabé A and Eiján AM: Cathepsin B is involved in the apoptosis intrinsic pathway induced by Bacillus Calmette-Guérin in transitional cancer cell lines. Int J Mol Med. 20:823–828. 2007.PubMed/NCBI

Sylvester RJ, Brausi MA, Kirkels WJ, Hoeltl W, Calais Da Silva F, Powell PH, Prescott S, Kirkali Z, van de Beek C, Gorlia T, et al: Long-Term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus calmette-guérin, and bacillus calmette-guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder. Eur Urol. 57:766–773. 2010. View Article : Google Scholar

Pook SH, Rahmat JNB, Esuvaranathan K and Mahendran R: Internalization of Mycobacterium bovis, Bacillus Calmette Guerin, by bladder cancer cells is cytotoxic. Oncol Rep. 18:1315–1320. 2007.PubMed/NCBI

Zhang G, Chen F, Cao Y, Amos JV, Shah G and See WA: HMGB1 release by urothelial carcinoma cells in response to bacillus calmette-guérin functions as a paracrine factor to potentiate the direct cellular effects of bacillus calmette-guérin. J Urol. 190:1076–1082. 2013. View Article : Google Scholar

Kawai K, Miyazaki J, Joraku A, Nishiyama H and Akaza H: Bacillus Calmette-Guerin (BCG) immunotherapy for bladder cancer: Current understanding and perspectives on engineered BCG vaccine. Cancer Sci. 104:22–27. 2013. View Article : Google Scholar

Muto S, Lu Y, Ide H, Yamaguchi R, Saito K, Kitamura K, Noma Y, Koyasu H, Hirano H, Ashizawa T, et al: The use of urine mycobacterium tuberculosis complex polymerase chain reaction as a predictive factor for recurrence and progression after intravesical bacillus calmette-guérin therapy in patients with non-muscle-invasive bladder cancer. Eur Urol Open Sci. 27:10–18. 2021. View Article : Google Scholar

Waked R, Choucair J, Chehata N, Haddad E and Saliba G: Intravesical Bacillus Calmette-Guérin (BCG) treatment's severe complications: A single institution review of incidence, presentation and treatment outcome. J Clin Tuberc Mycobact Dis. 19:1001492020.

Belldegrun AS, Franklin JR, O'Donnell MA, Gomella LG, Klein E, Neri R, Nseyo UO, Ratliff TL and Williams RD: Superficial bladder cancer: The role of interferon-alpha. J Urol. 159:1793–1801. 1998. View Article : Google Scholar

Samuel CE: Antiviral Actions of Interferons. Clin Microbiol Rev. 14:778–809. 2001. View Article : Google Scholar : PubMed/NCBI

Boorjian SA, Alemozaffar M, Konety BR, Shore ND, Gomella LG, Kamat AM, Bivalacqua TJ, Montgomery JS, Lerner SP, Busby JE, et al: Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: A single-arm, open-label, repeat-dose clinical trial. Lancet Oncol. 22:107–117. 2021. View Article : Google Scholar

Öhlund D, Elyada E and Tuveson D: Fibroblast heterogeneity in the cancer wound. J Exp Med. 211:1503–1523. 2014. View Article : Google Scholar

Hou R, Kong X, Yang B, Xie Y and Chen G: SLC14A1: A novel target for human urothelial cancer. Clin Transl Oncol. 19:1438–1446. 2017. View Article : Google Scholar

Ma Z, Li X, Mao Y, Wei C, Huang Z, Li G, Yin J, Liang X and Liu Z: Interferon-dependent SLC14A1+ cancer-associated fibroblasts promote cancer stemness via WNT5A in bladder cancer. Cancer Cell. 40:1550–1565.e7. 2022. View Article : Google Scholar

Lee A: Nadofaragene firadenovec: First approval. Drugs. 83:353–357. 2023. View Article : Google Scholar : PubMed/NCBI

Shepherd AR, Shepherd E and Brook NR: Intravesical Bacillus Calmette-Guérin with interferon-alpha versus intravesical Bacillus Calmette-Guérin for treating non-muscle-invasive bladder cancer. Cochrane Database Syst Rev. 3:CD0121122017.PubMed/NCBI

Pagès F, Lebel-Binay S, Vieillefond A, Deneux L, Cambillau M, Soubrane O, Debré B, Tardy D, Lemonne JL, Abastado JP, et al: Local immunostimulation induced by intravesical administration of autologous interferon-gamma-activated macrophages in patients with superficial bladder cancer. Clin Exp Immunol. 127:303–309. 2002. View Article : Google Scholar

Harris JR and Markl J: Keyhole limpet hemocyanin (KLH): A biomedical review. Micron. 30:597–623. 1999. View Article : Google Scholar : PubMed/NCBI

Dolashki A, Dolashka P, Stenzl A, Stevanovic S, Aicher WK, Velkova L, Velikova R and Voelter W: Antitumour activity of Helix hemocyanin against bladder carcinoma permanent cell lines. Biotechnol Biotechnol Equip. 33:20–32. 2019. View Article : Google Scholar

Lamm DL, DeHaven JI, Riggs DR and Ebert RF: Immunotherapy of murine bladder cancer with keyhole limpet hemocyanin (KLH). J Urol. 149:648–652. 1993. View Article : Google Scholar

Colotta F, Rambaldi A, Colombo N, Tabacchi L, Introna M and Mantovani A: Effect of a streptococcal preparation (OK432) on natural killer activity of tumour-associated lymphoid cells in human ovarian carcinoma and on lysis of fresh ovarian tumour cells. Br J Cancer. 48:515–525. 1983. View Article : Google Scholar : PubMed/NCBI

Yamaguchi Y, Ohshita A, Kawabuchi Y, Hihara J, Miyahara E, Noma K and Toge T: Locoregional immunotherapy of malignant ascites from gastric cancer using DTH-oriented doses of the streptococcal preparation OK-432: Treatment of Th1 dysfunction in the ascites microenvironment. Int J Oncol. 24:959–966. 2004.

Huang H, Kong D, Liu Y, Cui Q, Wang K, Zhang D, Wang J, Zhai M, Yan J, Zhang C and Wu G: Sapylin promotes wound healing in mouse skin flaps. Am J Transl Res. 9:3017–3026. 2017.PubMed/NCBI

Liu ZH, Zheng FF, Mao YL, Ye LF, Bian J, Lai DH, Ye YL and Dai YP: Effects of programmed death-ligand 1 expression on OK-432 immunotherapy following transurethral resection in non-muscle invasive bladder cancer. Oncol Lett. 13:4818–4824. 2017. View Article : Google Scholar

Fujita K: The role of adjunctive immunotherapy in superficial bladder cancer. Cancer. 59:2027–2030. 1987. View Article : Google Scholar : PubMed/NCBI

Speth PA, van Hoesel QG and Haanen C: Clinical pharmacokinetics of doxorubicin. Clin Pharmacokinet. 15:15–31. 1988. View Article : Google Scholar

Badalament RA and Farah RN: Treatment of superficial bladder cancer with intravesical chemotherapy. Semin Surg Oncol. 13:335–341. 1997. View Article : Google Scholar

Zincke H, Utz DC, Taylor WF, Myers RP and Leary FJ: Influence of thiotepa and doxorubicin instillation at time of transurethral surgical treatment of bladder cancer on tumor recurrence: A prospective, randomized, double-blind, controlled trial. J Urol. 129:505–509. 1983. View Article : Google Scholar

Kurth K, Tunn U, Ay R, Schröder FH, Pavone-Macaluso M, Debruyne F, ten Kate F, de Pauw M and Sylvester R: Adjuvant chemotherapy for superficial transitional cell bladder carcinoma: Long-term results of a European Organization for Research and Treatment of Cancer randomized trial comparing doxorubicin, ethoglucid and transurethral resection alone. J Urol. 158:378–384. 1997. View Article : Google Scholar

Yee SB and Pritsos CA: Reductive activation of doxorubicin by xanthine dehydrogenase from EMT6 mouse mammary carcinoma tumors. Chem Biol Interact. 104:87–101. 1997. View Article : Google Scholar

Niijima T, Koiso K and Akaza H: Randomized clinical trial on chemoprophylaxis of recurrence in cases of superficial bladder cancer. Cancer Chemother Pharmacol. 11 (Suppl):S79–S82. 1983. View Article : Google Scholar

Rivankar S: An overview of doxorubicin formulations in cancer therapy. J Cancer Res Ther. 10:853–858. 2014. View Article : Google Scholar : PubMed/NCBI

Yang JY, Wei W, Lan YL, Liu JQ, Wang HB and Li S: Role of bladder hydrodistention and intravesical sodium hyaluronate in the treatment of interstitial cystitis. Urol J. 12:2417–2421. 2015.PubMed/NCBI

Batts CN: Adjuvant intravesical therapy for superficial bladder cancer. Ann Pharmacother. 26:1270–1276. 1992. View Article : Google Scholar : PubMed/NCBI

Xue R, Zhao C, Chen D, Wang P, Xing W, Zeng W and Li Q: Potential influence of anaesthesia techniques on the recurrence and progression after resection of non-muscle-invasive bladder cancer: A propensity score-matched analysis. BMC Anesthesiol. 22:2632022. View Article : Google Scholar

Teng X, Liu Y, Wang L and Wang G: Lidocaine exerts anticancer activity in bladder cancer by targeting isoprenylcysteine carboxylmethyltransferase (ICMT). Transl Androl Urol. 10:4219–4230. 2021. View Article : Google Scholar

Yang X, Zhao L, Li M, Yan L, Zhang S, Mi Z, Ren L and Xu J: Lidocaine enhances the effects of chemotherapeutic drugs against bladder cancer. Sci Rep. 8:5982018. View Article : Google Scholar : PubMed/NCBI

Böhle A, Leyh H, Frei C, Kühn M, Tschada R, Pottek T, Wagner W, Knispel HH, von Pokrzywnitzki W, Zorlu F, et al: Single postoperative instillation of gemcitabine in patients with non-muscle-invasive transitional cell carcinoma of the bladder: A randomised, double-blind, placebo-controlled phase III multicentre study. Eur Urol. 56:495–503. 2009. View Article : Google Scholar

Chen SY, Du LD and Zhang YH: Pilot study of intravesical instillation of two new generation anthracycline antibiotics in prevention of superficial bladder cancer recurrence. Chin Med J (Engl). 123:3422–3426. 2010.PubMed/NCBI

Cozzi PJ, Bajorin DF, Tong W, Nguyen H, Scott J, Heston WD and Dalbagni G: Toxicology and pharmacokinetics of intravesical gemcitabine: A preclinical study in dogs. Clin Cancer Res. 5:2629–2637. 1999.PubMed/NCBI

Beaussier M, Delbos A, Maurice-Szamburski A, Ecoffey C and Mercadal L: Perioperative use of intravenous lidocaine. Drugs. 78:1229–1246. 2018. View Article : Google Scholar : PubMed/NCBI

Pederzoli F, Bandini M, Raggi D, Marandino L, Basile G, Alfano M, Colombo R, Salonia A, Briganti A, Gallina A, et al: Is there a detrimental effect of antibiotic therapy in patients with muscle-invasive bladder cancer treated with neoadjuvant pembrolizumab? Eur Urol. 80:319–322. 2021. View Article : Google Scholar